首页> 外文期刊>The journal of trauma and acute care surgery >Continuous noninvasive respiratory volume monitoring for the identification of patients at risk for opioid-induced respiratory depression and obstructive breathing patterns
【24h】

Continuous noninvasive respiratory volume monitoring for the identification of patients at risk for opioid-induced respiratory depression and obstructive breathing patterns

机译:连续无创呼吸量监测,以识别存在阿片类药物引起的呼吸抑制和阻塞性呼吸模式的风险的患者

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Opioid-induced respiratory depression (OIRD) and postoperative apnea (POA) can lead to complications after surgery or traumatic injury. Previously, real-time monitoring of respiratory insufficiency and identification of apneic events have been difficult. A noninvasive respiratory volume monitor (RVM) that reports minute ventilation (MV), tidal volume, and respiratory rate is now available. The RVM was used to report the effect of opioids on respiratory status as well as demonstrate apneic breathing patterns in a hospital postanesthesia care unit. METHODS: RVM traces were collected from 132 patients. Predicted MV (MVPRED) for each patient was used to calculate and the "percent predicted" MV (MVMEASURED / MVPRED × 100%) before opioid administration. Patients were stratified patients into two categories: "at risk," MV of less than 80% MVPRED, and "not at risk," MV of 80% MVPRED or greater. After opioid dosing, patients with MV of less than 40% MVPRED were categorized as "unsafe." POA was defined as more than five apneic or hypopneic events per hour. RESULTS: Of the 132 patients, 50 received opioids. Baseline MV was 7.2 ± 0.5 L/min. The MV-based protocol classified 18 of 50 patients as at risk before opioid administration. After the first opioid dose administration, at-risk patients experienced an average MV decrease (36.7% ± 8.5% MVPRED) and 13 of 18 decreased into unsafe; the 32 not at-risk patients experienced a lesser average MV decrease (76.9% ± 6.3% MVPRED). Only 1 of 32 not at-risk patients had a decrease in MV to unsafe. The proposed protocol had a sensitivity of 93% and a specificity of 86%. Of the 132 patients, 26 displayed POA. Of the 26 patients, 12 experienced POA without receiving opioids. Of the 26 patients with POA, 14 also received opioids, and of those, 6 were classified as unsafe. CONCLUSION: This investigation indicates that at risk and unsafe respiratory patterns occur frequently after procedure. RVM provides continuous noninvasive objective measurements of OIRD and POA. The RVM may prove a useful tool in opioid dosing and in recognition and management of POA and strong potential value in the rapid detection of OIRD and apnea in the contemporary combat casualty environment. LEVEL OF EVIDENCE: Care management study, level V.
机译:背景:阿片类药物引起的呼吸抑制(OIRD)和术后呼吸暂停(POA)可能导致手术或外伤后并发症。以前,对呼吸功能不全的实时监控和呼吸暂停事件的识别一直很困难。现在可以使用无创呼吸量监测仪(RVM),该监测仪可报告分钟通气量(MV),潮气量和呼吸频率。 RVM被用于报告阿片类药物对呼吸状态的影响,并在医院麻醉后监护病房显示出呼吸暂停模式。方法:收集132例患者的RVM踪迹。使用每位患者的预测MV(MVPRED)和阿片类药物给药前的“预测百分比” MV(MVMEASURED / MVPRED×100%)。将患者分为两类:“有风险”,MV低于80%MVPRED,“无风险”,MV达80%MVPRED或更高。阿片类药物给药后,MV低于MVPRED的40%的患者被归类为“不安全”。 POA定义为每小时超过五次呼吸暂停或呼吸不足事件。结果:在132例患者中,有50例接受了阿片类药物治疗。基线MV为7.2±0.5L / min。基于MV的方案将50名阿片类药物给药前的18名患者划分为高危人群。首次服用阿片类药物后,高危患者的平均MV降低(36.7%±8.5%MVPRED),其中18例中有13例不安全; 32名非高危患者的平均MV下降幅度较小(MVPRED为76.9%±6.3%)。在32位非高危患者中,只有1位的MV降低至不安全。拟议的协议灵敏度为93%,特异性为86%。在132例患者中,有26例显示POA。在26例患者中,有12例未接受阿片类药物而经历了POA。在26名POA患者中,有14名还接受了阿片类药物治疗,其中6名被归类为不安全。结论:本研究表明,术后有频繁发生危险和不安全的呼吸模式。 RVM提供OIRD和POA的连续无创客观测量。 RVM可能在阿片类药物给药以及POA的识别和管理中被证明是有用的工具,并且在当代战斗伤亡环境中快速检测OIRD和呼吸暂停时具有很强的潜在价值。证据级别:护理管理研究,第五级。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号